Alx Oncology Holdings Inc Stock Price, News & Analysis

BURLINGAME, Calif., March 02, 2021 – ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced participation in a fireside chat at H.C. Wainwright’s Global Life Sciences Conference on March 9-10, 2021. Jaume Pons, Ph.D., and senior executives will provide insights during the virtual event. A prerecorded chat is set to release on March 9, 2021, at 7:00 a.m. Eastern Time, accessible via ALX Oncology's website. ALX Oncology focuses on immuno-oncology, developing therapies to block the CD47 checkpoint pathway, with its lead candidate ALX148 showing promising clinical results.

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced key milestones for 2021 following a successful 2020, which included an IPO and a secondary offering that raised approximately $394 million. The company initiated clinical trials for its lead candidate, ALX148, showing promising data in treating various cancers. Upcoming milestones include the initiation of multiple Phase 1 and 2 trials, with significant data readouts expected. ALX Oncology's cash reserves are projected to sustain operations through 2024, supporting ongoing clinical development and collaborations.

ALX Oncology (Nasdaq: ALXO) announced that Jaume Pons, Ph.D., its CEO, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on January 12 at 10:50 am ET. The presentation will be accessible via a live webcast, available on the Investors section of ALX Oncology’s website. Following the event, a replay of the webcast will be archived for 30 days. ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway, with its lead candidate, ALX148, showing promise in treating various cancers.

ALX Oncology Holdings Inc. (NASDAQ: ALXO) has been selected for addition to the NASDAQ Biotechnology Index, effective prior to market open on December 21, 2020. The NASDAQ Biotechnology Index tracks biotechnology and pharmaceutical companies on NASDAQ, calculated under a modified capitalization-weighted methodology. ALX Oncology focuses on therapies that block the CD47 checkpoint pathway, with its lead candidate, ALX148, showing promising clinical responses for various malignancies.

ALX Oncology Holdings Inc. (Nasdaq: ALXO) has successfully closed its underwritten public offering of 2,737,000 shares of common stock at a price of $76.00 per share, raising approximately $208.0 million in gross proceeds. This includes the full exercise of the underwriters' option for an additional 357,000 shares. The offering was managed by Jefferies, Credit Suisse, and Piper Sandler, among others. The funds raised will likely support the ongoing clinical development of ALX148, a promising treatment targeting CD47 in various cancers.

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced an upsized public offering of 2,380,000 shares at $76.00 each, projected to raise approximately $180.9 million before expenses. The offering is set to close on December 14, 2020, pending customary conditions. An additional 357,000 shares may be purchased by underwriters within 30 days. Noteworthy managers include Jefferies and Credit Suisse. The proceeds will support ALX Oncology's clinical development, particularly of ALX148, aimed at targeting various cancers by blocking the CD47 checkpoint pathway.

ALX Oncology Holdings Inc. (Nasdaq: ALXO) has initiated an underwritten public offering of 2,000,000 shares of its common stock, with plans to grant underwriters a 30-day option for an additional 300,000 shares. The proceeds from this offering are expected to support ongoing clinical development of ALX148, a next-generation cancer therapy targeting the CD47 pathway. Jefferies, Credit Suisse, and Piper Sandler are managing the offering. A registration statement has been filed with the SEC, but it has not yet become effective, meaning the offering is subject to market conditions.

ALX Oncology announced promising results from its clinical trial of ALX148 combined with rituximab for treating patients with advanced relapsed and refractory non-Hodgkin lymphoma (NHL). The updated data, presented at the 62nd ASH Annual Meeting, indicates a 70.0% objective response rate (ORR) among those receiving the higher 15 mg/kg dose. The treatment was well tolerated, with no dose-limiting toxicities reported, supporting further investigation in a Phase 2 program targeting a range of cancers. The data were cut off as of October 1, 2020.

ALX Oncology announced updates regarding its planned Phase 2 head and neck cancer studies for ALX148. The FDA has requested the completion of a standard non-clinical safety study prior to the initiation of the potentially pivotal trials. Enrollment is capped at 50 subjects, but no delays are expected in the clinical timelines. ALX148 has shown promising results in earlier studies, with a 75% overall response rate noted in a Phase 1b cohort. The company plans to advance ALX148 in combination with KEYTRUDA and intends to seek accelerated approval for HNSCC.